Closed · HT942526BCRPTBCCA · CFDA 12.420 · Discretionary

DoW Breast Cancer, Transformative Breast Cancer Consortium Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
September 30, 2026
Close date
1
Expected awards

The verdict

DoW Breast Cancer, Transformative Breast Cancer Consortium Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
1
expected award
12.420
CFDA program

Recently closed NOFO

This listing closed on September 30, 2026. CFDA 12.420 may re-announce under a new opportunity number. Historical award band was Varies by applicant.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed September 30, 2026

Posted May 4 Closes Sep 30

Est. Total Funding

$35,000,000

Expected Awards

1

Instrument

Cooperative Agreement

Description

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges.Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.

Catch-all / unrestricted eligibility mark · HT942526BCRPTBCCA

Grants.gov marks DoW Breast Cancer with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

More from Defense Health Agency Contracting Activity - DHACA

Closed Closed September 22, 2026

DoW Neurofibromatosis Synergistic Idea Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Investigator-Initiated Research Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Research Academy – Scholar Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Exploration-Hypothesis Development Award

View →
Open Closes November 18, 2026

DOW Combat Readiness – Medical Research Program Translational Research Award

View →

What to do next

DoW Breast Cancer is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants